ADP receptor antagonists targeting the P2Y12 receptor provide effective antithrombotic therapy by inhibiting platelet function, with ongoing research into their specific modes of action.
This review summarizes the mechanisms and clinical development of P2Y12 ADP receptor antagonists for antithrombotic therapy.
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
Wijeyeratne et al. (Tue,) conducted a review in Thrombosis. ADP receptor antagonists was evaluated. ADP receptor antagonists targeting the P2Y12 receptor provide effective antithrombotic therapy by inhibiting platelet function, with ongoing research into their specific modes of action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: